Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
暂无分享,去创建一个
J. Griffiths | M. Leach | P. Workman | I. Judson | A. Ramírez de Molina | J. Lacal | L. Jackson | N. M. Al-Saffar | H. Troy | B. Madhu | Yuen-Li Chung
[1] J. Lacal,et al. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action , 2004, Oncogene.
[2] D. Megías,et al. Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.
[3] E. Eisenhauer,et al. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.
[4] Z. Bhujwalla,et al. Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.
[5] C. Aoyama,et al. Structure and function of choline kinase isoforms in mammalian cells. , 2004, Progress in lipid research.
[6] A. Ramírez de Molina,et al. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. , 2004, Cancer letters.
[7] J. Lacal,et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells , 2003, Oncogene.
[8] J. Griffiths,et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. , 2003, Journal of the National Cancer Institute.
[9] P. Workman. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.
[10] P. Workman. Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.
[11] R. Rosell,et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.
[12] Jose M. Silva,et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.
[13] J. Walecki,et al. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. , 2002, International journal of radiation oncology, biology, physics.
[14] Paul Workman,et al. Translating basic cancer research into new cancer therapeutics. , 2002, Trends in molecular medicine.
[15] M O Leach,et al. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells , 2002, British Journal of Cancer.
[16] A. Ramírez de Molina,et al. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. , 2001, Biochemical and biophysical research communications.
[17] Lacal Jc. Choline kinase: a novel target for antitumor drugs. , 2001 .
[18] M. Leach,et al. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells , 2001, British Journal of Cancer.
[19] J. Lacal. Choline kinase: a novel target for antitumor drugs. , 2001, IDrugs : the investigational drugs journal.
[20] M. Leach,et al. Breast imaging technology: Imaging biochemistry - applications to breast cancer , 2000, Breast Cancer Research.
[21] P. Workman,et al. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.
[22] J. J. Mukherjee,et al. Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. , 2000, Cellular signalling.
[23] P. McSheehy. On the role of MRS in drug development , 1999, NMR in biomedicine.
[24] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.
[25] J. Lacal,et al. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. , 1999, Cancer research.
[26] J. Griffiths,et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis , 1999, British Journal of Cancer.
[27] Z. Bhujwalla,et al. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.
[28] T. Powles,et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.
[29] D. Vance,et al. Biochemical and Evolutionary Significance of Phospholipid Methylation* , 1998, The Journal of Biological Chemistry.
[30] N. J. McNally,et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.
[31] J. Lacal,et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design , 1997, Oncogene.
[32] S. Williams,et al. Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.
[33] H. Degani,et al. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. , 1996, Anticancer research.
[34] H. Degani,et al. Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.
[35] C. Kent,et al. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. , 1995, Archives of biochemistry and biophysics.
[36] Z. Kiss,et al. Wortmannin inhibits carcinogen‐stimulated phosphorylation of ethanolamine and choline , 1995, FEBS letters.
[37] C. Kent,et al. Eukaryotic phospholipid biosynthesis. , 1995, Annual review of biochemistry.
[38] D. Vance,et al. Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. , 1994, Journal of lipid research.
[39] Z. Darżynkiewicz,et al. Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. , 1994, Cytometry.
[40] S. Jackowski. Coordination of membrane phospholipid synthesis with the cell cycle. , 1994, The Journal of biological chemistry.
[41] A. Cuadrado,et al. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. , 1993, Oncogene.
[42] M. Leach,et al. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma , 1993, NMR in biomedicine.
[43] W. Negendank,et al. Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.
[44] U. Klose. In vivo proton spectroscopy in presence of eddy currents , 1990, Magnetic resonance in medicine.
[45] J. Exton. Signaling through phosphatidylcholine breakdown. , 1990, The Journal of biological chemistry.
[46] C. Kent,et al. The effect of polycyclic aromatic hydrocarbons on choline kinase activity in mouse hepatoma cells. , 1989, Biochimica et biophysica acta.
[47] P. Luyten,et al. Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge , 1988, Magnetic resonance in medicine.
[48] Roger J. Ordidge,et al. Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy , 1986 .
[49] Roger J. Ordidge,et al. Image selected in-vivo spectroscopy (ISIS) , 1985 .
[50] Hans Ulrich Bergmeyer,et al. Methods of Enzymatic Analysis , 2019 .
[51] S. Rose. Transformed cells. , 1949, Scientific American.